1. Scrip
  2. >>Therapy Areas
  3. >>Alimentary/Metabolic

Pfizer Advancing Once-Daily Danuglipron For Obesity

 
• By Jessica Merrill

A modified-release formulation of the oral GLP-1 has been selected for development, Pfizer said. Dose-optimization studies will begin in the second half of the year.

Pfizer
Pfizer updated investors on the development of danuglipron • Source: Shutterstock

Pfizer Inc. signaled it remains firmly footed in the obesity space, announcing on 11 July that it has selected a once-daily, modified-release formulation of its oral glucagon-like peptide-1 (GLP-1) receptor agonist danuglipron to advance in development.

Key Takeaways
  • The once-daily formulation of the GLP-1 agonist danuglipron uses modified release.
  • Pfizer will begin dose-optimization studies in the second half of 2024 evaluating multiple doses

The decision is based on the results of an ongoing pharmacokinetic and safety study evaluating immediate- and modified-release formulations of danuglipron in healthy adults

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Alimentary/Metabolic

More from Therapy Areas

Shionogi In $1bn Deal For Japan Tobacco’s Pharma Ops

 
• By Ian Haydock

Mid-sized Japanese pharma firm to acquire tobacco giant’s pharma operations and take private the listed Torii Pharmaceutical business, in bid to build sales reach and strengthen manufacturing.

Copycats Compound Novo’s Wegovy Growth Problems

 
• By Andrew McConaghie

The US FDA has ordered compounders of the Danish firm's obesity drug semaglutide to shut up shop later this month, but competition from Eli Lilly is only increasing.

First Win For AstraZeneca’s Enhertu In Early-Stage Breast Cancer Treatment

 
• By Andrew McConaghie

Already dominating in later lines of breast cancer treatment, Enhertu could now displace both chemotherapy combinations and Roche’s Kadcyla in early-stage HER2-positive patients.